Study of GS-3242 in Participants With HIV-1; Substudy-05

Completed · Phase 1

Conditions studied: HIV-1-infection

In brief

This study is part of a master study. The goal of master protocol (GS-US-544-5905, NCT05585307) is to learn how novel antiretrovirals (medicines that stop the virus from multiplying) affect the human immunodeficiency virus-1 (HIV-1) infection in people living with HIV (PWH). Substudy GS-US-544-5905-05 is to learn more about the study drug GS-3242 in PWH.

Key facts

Study ID
NCT07001319
Run by
Gilead Sciences
People needed
27
Starts
2025-05-29
Expected to finish
2026-04-16
Last updated by the study team
2026-05-11

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.